Impaired Cerebral Autoregulation-A Common Neurovascular Pathway in Diabetes may Play a Critical Role in Diabetes-Related Alzheimer’s Disease

Shashank Shekhar¹,2, Shaoxun Wang³, Paige N Mims³, Ezekiel Gonzalez-Fernandez², Chao Zhang³,⁵, Xiaochen He³, Catherine Y Liu³, Wenshan Lv³,⁴, Yangang Wang⁴, Juebin Huang¹, and Fan Fan³,*

¹Department of Neurology, University of Mississippi Medical Center, USA ²Institute of Clinical Medicine, University of Turku, Finland ³Department of Pharmacology and Toxicology, University of Mississippi Medical Center, USA ⁴Department of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao University, China ⁵Department of Urology, Fudan University, China

Abstract

Alzheimer’s disease (AD) is the leading cause of progressive degenerative dementia. The hallmark pathological features include beta amyloid deposition and neurofibrillary tangles. There has been a strong association of AD with Diabetes (DM) based on human studies and animal experiments. The hallmark features of AD seem to have an exaggerated presence in AD with DM, especially type 2 diabetes (T2D). In addition, insulin resistance is a common feature in both diseases and as such AD has been called type 3 diabetes. Furthermore, impairment of cerebral autoregulation has been reported in both animal and human diabetic subjects. Cerebral vascular impairment has also been implicated in the pathophysiology of AD. There is an urgent need to develop animal models of AD and DM to explore the neuropathological mechanisms of these disease and utilize such models to develop treatment strategies.

Keywords

Autoregulation; Myogenic response; Diabetes; Alzheimer’s; Dementia; Rat model; T2DN

Introduction

Alzheimer’s disease (AD) and diabetes (DM) are two of the leading ageing related disorders. AD prevalence accounts for an estimated 5.4 million Americans in 2016 [1], where as DM affects more than 29 million Americans in 2013 [2]. AD is the only leading cause of death (6th overall) [3] that lacks any therapy to slow or reverse its progression [4] followed by DM as the 7th leading cause of death in United States (US). The Medicare cost for the treatment of dementia and AD is $159 billion annually and is projected to rise to
$511 billion by 2040 [5,6]. Similarly, DM prevalence is projected to triple by 2050 which costed the nation $245 billion per year in 2012 [2]. These untreatable chronic disorders will become a major economic burden long term. Thus, there is an urgent need to understand the mechanisms of these diseases in order to develop new therapeutic strategies that delay their progression.

**Discussion**

**High comorbidity of DM and AD**

AD is one of the most common forms of progressive degenerative brain disorders resulting in dementia [7,8]. AD is characterized by a decline in short term memory, problem-solving, complex cognitive skills and later language dysfunction. Loss in ability to perform everyday activities requires constant nursing and long-term dependence. This decline occurs because of wide spread cortical neuronal loss in areas of brain responsible for cognitive function. Whereas, DM is a variable disorder of carbohydrate metabolism resulting in hyperglycemia, which, if persists chronically, can lead to systemic complications including cognitive impairment T2D, which begins as insulin resistance and is the most common form of DM. Numerous studies demonstrate that diabetics are at an increased risk of developing AD especially in the elderly. As a result, AD has been proposed as Type 3 DM in appropriate context [9]. Recent animal studies are proposing an increased association of T2D with AD [10,11]. This association has also been corroborated in human epidemiological studies [12,13].

A clear mechanism underlying AD has yet to be fully understood. Earlier hypotheses of neuro degeneration in AD relied heavily on cholinergic deficiency, extracellular amyloid beta (Aβ) plaque formation, and hyperphosphorylated Tau protein induced neurofibrillary tangles [14]. However, current treatments and clinical trials targeting these pathways, such as using inhibitors of acetylcholinesterase [15], and γ secretase [16–19] or immunotherapy targeting to Aβ and Tau [18], have not been proved to be able to stop or slow down the disease process of AD. Lack of effective pharmacological interventions has led the community to reconsider alternatives [14]. There is increased evidence indicating that cerebral vascular dysfunction plays an important role in the development of dementia and AD. A vascular pathogenesis has thus been proposed which comprises cerebral hypoperfusion, blood-brain barrier (BBB) dysfunction [14,20,21] and impaired cerebral microcirculation [22,23]. Diabetics with AD have increased numbers of beta amyloid plaques, tau-positive cells, advanced glycation end products and more activated microglia than the brains of AD patients without diabetes. These effects are markedly seen in the hippocampus [24]. The proposed mechanisms include insulin resistance [25], inflammation [26] and impaired glucose transporters [27]. However, there is additional impairment in cerebral autoregulation [28] resulting in microinfarction, hemorrhages, and eventual neuronal loss.

**Cerebral Autoregulation**

Cerebral autoregulation was first described by Lassen in 1959, where he reported clinical studies assessing cerebral blood flow [29]. Since then, cerebral autoregulation has been
broadly used to describe the local circulatory changes as well the global perfusion related changes in the brain [30]. For this review, we will use the cerebral autoregulation as blanket definition which encompasses both mechanoregulation as well chemoregulation. Perfusion related change occurring in large vessels has been described else where as mechanoregulation, where as, vascular changes occurring in response to changes in arterial CO2 is described as chemoregulation or metabolic regulation [30,31]. Furthermore, changes occurring locally around neurovascular junction are referred to as neurovascular coupling [30]. Cerebral autoregulation is an inherent mechanism where by the cerebral vasculature maintains constant cerebral blood flow by responding to systemic changes in blood pressure and thus maintaining neurovascular homeostasis [32–34]. Impaired cerebral autoregulation has been reported with advancing ageing [35–37], hypoxemia/ischemia [35] and hyperglycemia [38], suggesting these conditions are related to dysfunction at the autoregulatory pathway. Thus, it is important to understand the pathophysiology of cerebral autoregulation. The vessel’s ability to autoregulate with rise and drop in blood pressure is achieved mainly through myogenic response, and additional enhancement is achieved through metabolic activators [39]. Vascular smooth muscle cells (VSMC) are the main contractile vascular structures and are predominantly located in the wall of cerebral arteries as well pial and penetrating arterioles. These cells respond to pressure elevation by a constriction mechanism using Bayliss myogenic response [40]. Such response has been observed [33,34,41] in the middle cerebral artery territory (MCA) of the rats, where large diameter arteries (202 μm) display greater myogenic response between 60–100 mmHg, whereas penetrating arterioles (58 μm) show greater response between 20–16mmHg [42]. The myogenic response is enhanced by vasoconstrictors, e.g. Angiotensin II, ET1, and 20 HETE [33,43]. In contrast, during drop in blood pressure, vessels dilate in response to metabolic active vasodilators, e.g. Nitric Oxide (NO), endothelial derived hyperpolarizing factor, adenosine, extracellular K+, hydrogen ion, lactate, and carbon monoxide (CO) [44]. These metabolites are released at the level of neurovascular coupling from endothelial cells, and glial cells [45], including astrocytes [46], due to hypoxemia (reactive hyperemia) [47,48] or neuron activation (functional hyperemia) [45,49]. Thus, any dysfunction of these smooth muscles, endothelial and glial cells could result in autoregulatory dysfunction. Furthermore, the degree of vascular remodeling also contributes to the regulation of cerebral mechanoautoregulation. Increased vascular wall thickness and perivascular fibrosis could affect vascular compliance and decrease the ability of a blood vessel wall to expand in response to changes in blood pressure [50,51]. Enhanced vascular remodeling and decreased compliance has been reported in DM [52,53] as well in AD[54–56].

Cerebral autoregulation, DM and AD

Aging results in impairment of autoregulation which increases the risk of cerebral pathology including stroke, vascular cognitive impairment [57–60], and AD [60–62]. The risk is increased with coexistence of hypertension and diabetes [63]. With ageing, there is increased rarefaction of small penetrating arteries to deeper structures of the brain especially the basal ganglia and periventricular white matter [59,62,64]. This results in compromised regional blood flow and formation of lacunar infarctions, as well microbleeds, all of which are correlated with decline in cognitive function [62,65,66]. As ageing advances, there is BBB breakdown, vascular remodeling, glial cell activation, and inflammation further exacerbating...
the neurodegeneration [51,58–60,67,68]. Evidence suggests that the myogenic response of the MCA is impaired in AD [44] and DM [69]. Persistent hyperglycemia is associated with cerebral vascular dysfunction, BBB leakage, and inflammation that may contribute to the development of neurodegeneration and eventually dementia. In AD, there is reduction in number of microvessels, VSMCs and flattening of endothelial cells [70], suggesting AD may be linked to impaired cerebral autoregulation. The Atherosclerosis Risk in Communities-Neurocognitive Study (ARIC-NCS) population, especially the diabetic population, was noted to have mild cognitive impairment (the early stage of AD) [12]. Two-hit hypothesis was first described by Zlokovic, BV. According to this hypothesis, there are vascular mediated injuries occurring from DM, Hypertension, and Stroke, which ensue a non-amyloidogenic pathway resulting in dementia [21]. In DM, arteriosclerosis occurs due to glycosylation, and as a result, vessels lose the stretch reflex, transferring the arterial pressure to the capillaries which in turn results in vascular leakage through breakdown of the BBB and oligemia (local reduction in blood flow): this last step is described as first hit [21]. Consequently, the breakdown of BBB results in microinfarction, microbleeds, toxic accumulation and less clearance of Aβ proteins. Whereas, oligemia leads to APP expression and increased AB production which result in excess of Aβ: this step is described as second hit [21]. This furthers the cascade and thus perpetuates neuronal dysfunction and injury resulting in cognitive decline, and neurodegeneration [21,62,65].

Indeed, insulin resistance and glucose transporter dysfunction in the brain play important roles in T2D related AD. In a recent cohort study of about 1500 patients with T2D, researchers treated patients with Metformin vs. other hypoglycemic agents in order to observe change in cognition. They found that metformin intervention significantly reduced the risk of developing dementia by 20% when compared other diabetic therapies [71]. In another study, the use of sulfonylureas and metformin over 8 years, resulted in a decreased risk of dementia by 35% [72]. In addition, the amyloid precursor protein (APP) gene, which is associated with some cases of AD, has been shown to be involved in the insulin pathway. Therefore, impairment of this pathway can result in T2D [73]. On the other hand, impaired glucose utilization in mice via overexpression APP has been reported to cause derangement of CBF [74]. Furthermore, reduced expression of the glucose transporter GLUT1 [75,76] and GLUT3 [75,77] exacerbates AD, thus exacerbating the risk of dementia with each severe hypoglycemic episode in elderly diabetic patients [78–80].

**Ideal Animal Models for Future Studies**

To further elucidate the common pathology in AD and DM, there is need for an ideal animal model. A mixed mice model of T2D and AD has been generated by crossing APP/PS1 mice (AD model) with db/db mice (T2D model) [81]. This model exhibits microglia activation, BBB leakage, brain atrophy, and tau pathology. More recently, our group used a rat T2D model-T2DN, and found that it is associated with impaired autoregulation of CBF, glial activation, inflammation and Alzheimer-like cognitive deficits [82,83]. The T2DN rats closely mimic changes in diabetic patients and develops diabetic nephropathy at 6 months of age due to impaired renal autoregulation [84–86]. Nevertheless, both animal models exhibit cerebral vascular dysfunction suggesting a greater need to explore their common ground of vascular pathology.
Conclusion

AD and T2D are age dependent diseases. There are several potential mechanisms that have been proposed to be involved in the pathogenesis of AD including classical Aβ protein deposition, tau associated neurofibrillary tangles as well as the acetylcholine deficiency. Previous generations of treatment focusing on these mechanisms have failed to prevent the progression of AD, giving rise to the need for alternative therapeutic approaches. Recent studies have suggested that insulin resistance and cerebral autoregulation could be responsible for common pathogenesis in comorbid AD and DM. It is possible that impaired autoregulation is occurring very early before the onset of dementia. Whether this cerebral vascular dysfunction precedes neurodegeneration or whether it is simply an outcome of amyloid and tau deposition has yet to be validated. In order to identify this pathology and even to develop therapeutic interventions there is a great need for the development of an ideal animal model. The recent data on mixed T2D and AD mice and T2DN rat models are promising, however, further research is required to validate whether these models are ideal for mechanisms involved in “type 3 DM,” especially starting from the cerebral vascular function aspect.

Acknowledgments

This study was supported by grants AG050049 (FF), P20GM104357 (FF) from the National Institutes of Health, and 16GRNT31200036 (FF) from the American Heart Association. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Abbreviations

| Abbreviation | Description                  |
|--------------|------------------------------|
| AD           | Alzheimer’s Disease          |
| DM           | Diabetes                     |
| T2D          | Type 2 diabetes              |
| Aβ           | Amyloid Beta                 |
| VSMC         | Vascular Smooth Muscle Cells |
| CO2          | Carbon Dioxide               |
| ARIC-NCS     | Atherosclerosis Risk in Communities-Neurocognitive Study |
| BBB          | Blood Brain Barrier          |
| APP          | Amyloid Precursor Protein    |
| MCA          | Middle Cerebral Artery       |

References

1. Alzheimer’s, Association. Alzheimer’s disease facts and figures. Alzheimers Dementia. 2016; 12(4): 459–509.
2. Centers for Disease Control and Prevention. National diabetes statistics report: estimates of diabetes and its burden in the United States. Centers for Disease Control and Prevention; 2015.
3. Kochanek KD, Murphy SL, Xu J, Tejada-Vera B. Deaths: Final Data for 2014. Natl Vital Stat Rep. 2016; 65(4):1–122.
4. Godyn J, Jonczyk J, Panek D, Malawska B. Therapeutic strategies for Alzheimer’s disease in clinical trials. Pharmacol Rep. 2016; 68(1):127–138. [PubMed: 26721364]
5. Yang Z, Lin PJ, Levey A. Monetary costs of dementia in the United States. N Engl J Med. 2013; 369(5):489.
6. Blackwell DL, Lucas JW, Clarke TC. Summary health statistics for U.S. adults: national health interview survey, 2012. Vital Health Stat. 2014; 10(260):1–161.
7. Wilson RS, Segawa E, Boyle PA, Anagno SE, Hizel LF, et al. The natural history of cognitive decline in Alzheimer’s disease. Psychol Aging. 2012; 27(4):1008–1017. [PubMed: 22946521]
8. Barker WW, Luis CA, Kashuba A, Luis M, Harwood DG, et al. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord. 2002; 16(4):203–212. [PubMed: 12468894]
9. Kandimalla R, Thirumala V, Reddy PH. Is Alzheimer’s disease a Type 3 Diabetes? A critical appraisal. Biochim Biophys Acta. 2017; 1863(5):1078–1089. [PubMed: 27567931]
10. Lannert H, Hoyer S. Intracerebroventricular administration of streptozotocin causes long-term diminishments in learning and memory abilities and in cerebral energy metabolism in adult rats. Behav Neurosci. 1998; 112(5):1199–1208. [PubMed: 9829797]
11. Hoyer S, Lannert H. Inhibition of the neuronal insulin receptor causes Alzheimer-like disturbances in oxidative/energy brain metabolism and in behavior in adult rats. Ann N Y Acad Sci. 1999; 893:301–303. [PubMed: 10672254]
12. Knopman DS, Gottesman RF, Sharrett AR, Wruck LM, Windham BG, et al. Mild Cognitive Impairment and Dementia Prevalence: The Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS). Alzheimers Dement (Amst). 2016; 2:1–11. [PubMed: 26949733]
13. Mayeda ER, Haan MN, Neuhaus J, Yaffe K, Knopman DS, et al. Type 2 diabetes and cognitive decline over 14 years in middle-aged African Americans and whites: the ARIC Brain MRI Study. Neuroepidemiology. 2014; 43(3–4):220–227. [PubMed: 25402639]
14. Shaoxun Wang PNM, Richard J, Roman Fan Fan. Is Beta-Amyloid Accumulation a Cause or Consequence of Alzheimer’s Disease? Journal of Alzheimer’s Parkinsonism & Dementia. 2016; 1(2):1–4.
15. McGleenon BM, Dyman KB, Passmore AP. Acetylcholinesterase inhibitors in Alzheimer’s disease. Br J Clin Pharmacol. 1999; 48(4):471–480. [PubMed: 10583015]
16. Siemens ER, Quinn JJ, Kaye J, Farlow MR, Porsteinsson A, et al. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology. 2006; 66(4):602–604. [PubMed: 16505324]
17. Fleisher AS, Raman R, Siemens ER, Becerra L, Clark CM, et al. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol. 2008; 65(8):1031–1038. [PubMed: 18695053]
18. Doody RS, Aisen PS, Ivatsubo T. Semagacestat for treatment of Alzheimer’s disease. N Engl J Med. 2013; 369(17):1661.
19. Doody RS, Raman R, Farlow M, Ivatsubo T, Vellas B, et al. Phase 3 trial of semagacestat for treatment of Alzheimer’s disease. N Engl J Med. 2013; 369(4):341–350. [PubMed: 23883379]
20. Kelleher RJ, Soiza RL. Evidence of endothelial dysfunction in the development of Alzheimer’s disease: Is Alzheimer’s a vascular disorder? Am J Cardiovasc Dis. 2013; 3(4):197–226. [PubMed: 24224133]
21. Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. Nat Rev Neurosci. 2011; 12(12):723–738. [PubMed: 22048062]
22. de la Torre JC, Massivand T. Can disturbed brain microcirculation cause Alzheimer’s disease? Neurol Res. 1993; 15(3):146–153.
23. Stopa EG, Butala P, Salloway S, Johanson CE, Gonzalez L, et al. Cerebral cortical arteriolar angiopathy, vascular beta-amyloid, smooth muscle actin, Braak stage, and APOE genotype. Stroke. 2008; 39(3):814–821. [PubMed: 18258839]
24. Valente T, Gella A, Fernandez-Busquets X, Unzeta M, Durany N. Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer’s disease and diabetes mellitus. Neurobiol Dis. 2010; 37(1):67–76. [PubMed: 19778613]

25. Ott A, Stolk RP, Hofman A, van Harskamp F, Grobbee DE, et al. Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia. 1996; 39(11):1392–1397. [PubMed: 8933010]

26. Saraswathi V, Rammanan CJ, Wilks AW, Desouza CV, Eller AA, et al. Impact of hematopoietic cyclooxygenase-1 deficiency on obesity-linked adipose tissue inflammation and metabolic disorders in mice. Metabolism. 2013; 62(11):1673–1685. [PubMed: 23987235]

27. Lyros E, Bakogiannis C, Liu Y, Fassbender K. Molecular links between endothelial dysfunction and neurodegeneration in Alzheimer’s disease. Curr Alzheimer Res. 2014; 11(1):18–26. [PubMed: 24251393]

28. Mankovsky BN, Piolot R, Mankovsky OL, Ziegler D. Impairment of cerebral autoregulation in diabetic patients with cardiovascular autonomic neuropathy and orthostatic hypotension. Diabet Med. 2003; 20(2):119–126. [PubMed: 12581263]

29. Lassen NA. Cerebral blood flow and oxygen consumption in man. Physiol Rev. 1959; 39(2):183–238. [PubMed: 13645234]

30. Claassen JA, Zhang R. Cerebral autoregulation in Alzheimer’s disease. J Cereb Blood Flow Metab. 2011; 31(7):1572–1577.

31. Lavi S, Gaitini D, Milloul V, Jacob G. Impaired cerebral CO2 vasoreactivity: association with endothelial dysfunction. Am J Physiol Heart Circ Physiol. 2006; 291(4):H1856–1861. [PubMed: 16766649]

32. Paulson OB, Strandgaard S, Edvinsson L. Cerebral autoregulation. Cerebrovasc Brain Metab Rev. 1990; 2(2):161–192. [PubMed: 2201348]

33. Fan F, Geurts AM, Murphy SR, Pabbidi MR, Jacob HJ, et al. Impaired myogenic response and autoregulation of cerebral blood flow is rescued in CYP4A1 transgenic Dahl salt-sensitive rat. Am J Physiol Regul Integr Comp Physiol. 2015; 308(5):R379–390. [PubMed: 25540098]

34. Fan F, Geurts AM, Pabbidi MR, Smith SV, Harder DR, et al. Zinc-finger nuclease knockout of dual-specificity protein phosphatase-5 enhances the myogenic response and autoregulation of cerebral blood flow in FHH.1BN rats. PLoS One. 2014; 9(11):e112878. [PubMed: 25397684]

35. Popa-Wagner A, Buga AM, Popescu B, Muresanu D. Vascular cognitive impairment, dementia, aging and energy demand. A vicious cycle. J Neural Transm (Vienna). 2015; 122(1):S47–54. [PubMed: 24337666]

36. Brown WR, Thore CR. Review: cerebral microvascular pathology in ageing and neurodegeneration. Neuropathol Appl Neurobiol. 2011; 37(1):56–74. [PubMed: 20946471]

37. van Beek AH, Claassen JA, Rikkert MG, Jansen RW. Cerebral autoregulation: an overview of current concepts and methodology with special focus on the elderly. J Cereb Blood Flow Metab. 2008; 28(6):1071–1085. [PubMed: 18349877]

38. Caballero AE, Arora S, Saouaf R, Lim SC, Smakowski P, et al. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes. 1999; 48(9):1856–1862. [PubMed: 10480619]

39. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev. 2002; 82(1):131–185. [PubMed: 11773611]

40. Bayliss WM. On the local reactions of the arterial wall to changes of internal pressure. J Physiol. 1902; 28(3):220–231. [PubMed: 16992618]

41. Stunkard AJ. Obesity and the social environment: current status, future prospects. Ann N Y Acad Sci. 1977; 300:298–320. [PubMed: 279276]

42. Golding EM, Robertson CS, Bryan RM. Comparison of the myogenic response in rat cerebral arteries of different calibers. Brain Res. 1998; 785(2):293–298. [PubMed: 9518656]

43. Gebremedhin D, Lange AR, Lowry TF, Taheri MR, Birks EK, et al. Production of 20-HETE and its role in autoregulation of cerebral blood flow. Circ Res. 2000; 87(1):60–65. [PubMed: 10884373]

44. Girouard H, Iadecola C. Neurovascular coupling in the normal brain and in hypertension, stroke, and Alzheimer disease. J Appl Physiol (1985). 2006; 100(1):328–355. [PubMed: 16357086]

45. Attwell D, Buchan AM, Charpak S, Lauritzen M, Macvicar BA, et al. Glial and neuronal control of brain blood flow. Nature. 2010; 468(7321):232–243. [PubMed: 21068832]
46. Koehler RC, Roman RJ, Harder DR. Astrocytes and the regulation of cerebral blood flow. Trends Neurosci. 2009; 32(3):160–169. [PubMed: 19162338]
47. Sundt TM, Waltz AG. Cerebral ischemia and reactive hyperemia. Studies of cortical blood flow and microcirculation before, during, and after temporary occlusion of middle cerebral artery of squirrel monkeys. Circ Res. 1971; 28(4):426–433. [PubMed: 4994637]
48. Cohan SL, Mun SK, Petite J, Correia J, Tavela Da Silva AT, et al. Cerebral blood flow in humans following resuscitation from cardiac arrest. Stroke. 1989; 20(6):761–765. [PubMed: 2728042]
49. Newman EA. Functional hyperemia and mechanisms of neurovascular coupling in the retinal vasculature. J Cereb Blood Flow Metab. 2013; 33(11):1685–1695. [PubMed: 23963372]
50. Baumbach GL, Heistad DD. Cerebral circulation in chronic arterial hypertension. Hypertension. 1988; 12(2):89–95. [PubMed: 3044994]
51. Iadecola C, Davison RL. Hypertension and cerebrovascular dysfunction. Cell Metab. 2013; 33(11):1685–1695. [PubMed: 23963372]
52. Zampetaki A, Xu Q. Vascular remodeling in diabetes: don’t leave without your STAT5. Arterioscler Thromb Vasc Biol. 2009; 29(1):10–11. [PubMed: 19092137]
53. Schaper W, Buschmann I. Collateral circulation and diabetes. Circulation. 1999; 99(17):2224–2226. [PubMed: 10226084]
54. Meyer EP, Ullmann-Schuler A, Staufenbiel M, Krucker T. Altered morphology and 3D architecture of brain vasculature in a mouse model for Alzheimer’s disease. Proc Natl Acad Sci. 2008; 105(9):3587–3592. [PubMed: 18305170]
55. Joo IL, Lai AY, Bazzigaluppi P, Koletar MM, Dorr A, et al. Early neurovascular dysfunction in a transgenic rat model of Alzheimer’s disease. Sci Rep. 2017; 7:46427. [PubMed: 28401931]
56. Attems J, Lauda F, Jellinger KA. Unexpectedly low prevalence of intracerebral hemorrhages in sporadic cerebral amyloid angiopathy: an autopsy study. J Neurol. 2008; 255(1):70–76. [PubMed: 18202817]
57. Bidani AK, Griffin KA, Williamson G, Wang X, Loutzenhisre R. Protective importance of the myogenic response in the renal circulation. Hypertension. 2009; 54(2):393–398. [PubMed: 19546375]
58. Lammie GA. Hypertensive cerebral small vessel disease and stroke. Brain Pathol. 2002; 12(3):358–370. [PubMed: 12146804]
59. Faraco G, Iadecola C. Hypertension: a harbinger of stroke and dementia. Hypertension. 2013; 62(5):810–817. [PubMed: 23980072]
60. Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American heart association/american stroke association. Stroke. 2011; 42(9):2672–2713. [PubMed: 21778438]
61. de la Torre JC. Cerebromicrovascular pathology in Alzheimer’s disease compared to normal aging. Gerontology. 1997; 43(1–2):63–66. [PubMed: 8996828]
62. Brickman AM, Guzman VA, Gonzalez-Castellon M, Razlighi Q, Gu Y, et al. Cerebral autoregulation, beta amyloid, and white matter hyperintensities are interrelated. Neurosci Lett. 2015; 592:54–58. [PubMed: 25748319]
63. Pires PW, Dams Ramos CM, Matin N, Dorrance AM. The effects of hypertension on the cerebral circulation. Am J Physiol Heart Circ Physiol. 2013; 304(12):H1598–H1614. [PubMed: 23585339]
64. Federico A, Di Donato I, Bianchi S, Di Palma C, Taglia I, et al. Hereditary cerebral small vessel diseases: a review. J Neurol Sci. 2012; 322(1–2):25–30. [PubMed: 22860808]
65. Hainsworth AH, Markus HS. Do in vivo experimental models reflect human cerebral small vessel disease? A systematic review. J Cereb Blood Flow Metab. 2008; 28(12):1877–1891. [PubMed: 18698331]
66. Strandgaard S. Cerebral blood flow in the elderly: impact of hypertension and antihypertensive treatment. Cardiovasc Drugs Ther. 1991; 4(6):1217–1221. [PubMed: 2090245]
67. Jiwa NS, Garrard P, Hainsworth AH. Experimental models of vascular dementia and vascular cognitive impairment: a systematic review. J Neurochem. 2010; 115(4):814–828. [PubMed: 20731763]
68. Dahlof B. Prevention of stroke in patients with hypertension. Am J Cardiol. 2007; 100(3A):17J–24J.
69. Kelly-Cobbs AI, Prakash R, Coucha M, Knight RA, Li W, et al. Cerebral myogenic reactivity and blood flow in type 2 diabetic rats: role of peroxynitrite in hypoxia-mediated loss of myogenic tone. J Pharmacol Exp Ther. 2012; 342(2):407–415. [PubMed: 22570365]
70. Farkas E, Luiten PG. Cerebral microvascular pathology in aging and Alzheimer’s disease. Prog Neurobiol. 2001; 64(6):575–611. [PubMed: 11311463]
71. Knopman, D., et al. Metformin Cuts Dementia Risk in Type 2 Diabetes. Alzheimer Association International; Boston MA: 2013.
72. Hsu CC, Wahlqvist ML, Lee MS, Tsai HN. Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. J Alzheimers Dis. 2011; 24(3):485–493. [PubMed: 21297276]
73. Suzuki N, Cheung TT, Cai XD, Odaka A, Otvos L, et al. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science. 1994; 264(5163):1336–1340. [PubMed: 8191290]
74. Niwa K, Kazama K, Younkin SG, Carlson GA, Iadecola C. Alterations in cerebral blood flow and glucose utilization in mice overexpressing the amyloid precursor protein. Neurobiol Dis. 2002; 9(1):61–68. [PubMed: 11848685]
75. Simpson IA, Chundu KR, Davies-Hill T, Honer WG, Davies P. Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer’s disease. Ann Neurol. 1994; 35(5):546–551. [PubMed: 8179300]
76. Winkler EA, Nishida Y, Sagare AP, Rege SV, Bell RD, et al. GLUT1 reductions exacerbate Alzheimer’s disease vasculo-neuronal dysfunction and degeneration. Nat Neurosci. 2015; 18(4):521–530. [PubMed: 25730668]
77. Harr SD, Simonian NA, Hyman BT. Functional alterations in Alzheimer’s disease: decreased glucose transporter 3 immunoreactivity in the perforant pathway terminal zone. J Neuropathol Exp Neurol. 1995; 54(1):38–41. [PubMed: 7815078]
78. Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA. 2009; 301(15):1565–1572. [PubMed: 19367766]
79. Meneilly GS, Tessier DM. Diabetes, Dementia and Hypoglycemia. Can J Diabetes. 2016; 40(1):73–76. [PubMed: 26778684]
80. Yaffe K, Falvey CM, Hamilton N, Harris TB, Simonsick EM, et al. Association between hypoglycemia and dementia in a biracial cohort of older adults with diabetes mellitus. JAMA Intern Med. 2013; 173(14):1300–1306. [PubMed: 23753199]
81. Ramos-Rodriguez JJ, Jimenez-Palomares M, Murillo-Carretero MI, Infante-Garcia C, Berrocoso E, et al. Central vascular disease and exacerbated pathology in a mixed model of type 2 diabetes and Alzheimer’s disease. Psychoneuroendocrinology. 2015; 62:62–79. [PubMed: 26254770]
82. Lv W, Yu H, Li L, Taylor C, Gonzalez-Fernandez E, et al. Abstract P243: A New Type 2 Diabetic Rat Model That is Associated with Cognitive Impairment in Aging. Hypertension. 2016; 68(1):AP243–AP243.
83. Sims J, Elliott M, Roman R, Fan F. Impaired autoregulation of cerebral blood flow on cognitive decline in aging diabetes. Diabetes. 2016; 65(1):479P–479P.
84. Nobrega MA, Fleming S, Roman RJ, Shiozawa M, Schlick N, et al. Initial characterization of a rat model of diabetic nephropathy. Diabetes. 2004; 53(3):735–742. [PubMed: 14988259]
85. Kojima N, Slaughter T, Paige A, Kato S, Roman R. Comparison of the Development Diabetic Induced Renal Disease in Strains of Goto-Kakizaki Rats. J Diabetes Metab S. 2013; 9(5):S9–005.
86. Kojima N, Williams JM, Takahashi T, Miyata N, Roman RJ. Effects of a New SGLT2 Inhibitor, Luseogliflozin, on Diabetic Nephropathy in T2DN Rats. J Pharmacol Exp Ther. 2013; 345(3):464–472. [PubMed: 23492941]